Richard Johnson is a Nephrology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12700 E 19th Ave
Aurora, CO 800452560
Telephone
303-724-4852Registry record last updated 19 Nov 2012.
Clinical trials
- Breast Reconstruction Outcomes With and Without StratticE
Sponsor: Manchester University NHS Foundation Trust
- Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru
Sponsor: University of Colorado, Denver
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SOBI, INCProgram year202510 payments
- Amgen Inc.Program year20251 payment
- Amgen Inc.Program year20245 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
82.3%Calcium channel blocker31.2%Amlodipine Besylate100%Part D<11 patientsAngiotensin receptor blocker (ARB)26%Losartan Potassium100%Part D<11 patients+ 2 more classes in this area
Musculoskeletal
17.7%Xanthine oxidase inhibitor17.7%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
14 NIH research awards on record, funded 2008–2024 per NIH RePORTER. The latest:
- Renal and Electrolyte Disease and Hypertension
University of Colorado Denver
FY2024$310,248T32DK007135 - Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
Colorado Research Partners, Llc
FY2023$1,151,963U01AA027997 - Silica Nephropathy and Chronic Kidney Disease of Unknown Etiology
University of Colorado Denver
FY2023$629,682R01DK125351
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”